BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,854 | $2,419 | $2,096 | $1,846 |
| % Growth | 18% | 15.4% | 13.5% | – |
| Cost of Goods Sold | $580 | $532 | $503 | $471 |
| Gross Profit | $2,274 | $1,887 | $1,593 | $1,376 |
| % Margin | 79.7% | 78% | 76% | 74.5% |
| R&D Expenses | $747 | $747 | $650 | $629 |
| G&A Expenses | $532 | $404 | $373 | $354 |
| SG&A Expenses | $1,009 | $892 | $823 | $759 |
| Sales & Mktg Exp. | $477 | $488 | $450 | $405 |
| Other Operating Expenses | $33 | $62 | -$41 | $70 |
| Operating Expenses | $1,789 | $1,701 | $1,432 | $1,458 |
| Operating Income | $484 | $186 | $161 | -$82 |
| % Margin | 17% | 7.7% | 7.7% | -4.5% |
| Other Income/Exp. Net | $58 | $3 | -$11 | $7 |
| Pre-Tax Income | $542 | $189 | $150 | -$75 |
| Tax Expense | $115 | $21 | $8 | -$11 |
| Net Income | $427 | $168 | $142 | -$64 |
| % Margin | 15% | 6.9% | 6.8% | -3.5% |
| EPS | 2.25 | 0.89 | 0.76 | -0.35 |
| % Growth | 152.8% | 17.1% | 317.1% | – |
| EPS Diluted | 2.21 | 0.88 | 0.75 | -0.35 |
| Weighted Avg Shares Out | 190 | 188 | 185 | 183 |
| Weighted Avg Shares Out Dil | 197 | 192 | 189 | 183 |
| Supplemental Information | – | – | – | – |
| Interest Income | $75 | $58 | $18 | $10 |
| Interest Expense | $13 | $17 | $16 | $15 |
| Depreciation & Amortization | $96 | $104 | $102 | $108 |
| EBITDA | $651 | $307 | $265 | $47 |
| % Margin | 22.8% | 12.7% | 12.7% | 2.6% |